A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label study examining the safety and tolerability of sotrovimab, administered
in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral
immunity against SARS-CoV-2.
Phase:
Phase 2
Details
Lead Sponsor:
Sophia Koo, M.D.
Collaborators:
Dana-Farber Cancer Institute GlaxoSmithKline Massachusetts General Hospital